Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: Therapeutic and pharmacoeconomic perspectives

Aguilar Ponce, José Luis; Flores Pizaco, Yolanda; Pérez Urizar, José; Castañeda Hernández, Gilberto; Zinser Sierra, Juan W; Dueñas González, Alfonso; Calderón Flores, Ernesto; Segura Pacheco, Blanca Angélica; de la Garza Salazar, Jaime.
Arch. med. res ; 30(3): 212-5, mayo-jun. 1999. tab, graf
Artículo en Inglés | LILACS | ID: lil-256650

Documentos relacionados

  1. [Epigenetic effects affecting etoposide distribution and metabolism in the human body].
  2. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.
  3. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
  4. Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs.
  5. KCTD5 regulates Ikaros degradation induced by chemotherapeutic drug etoposide in hematological cells.
  6. Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
  7. A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats.
  8. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats.
  9. A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats.
  10. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.